The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II evaluation of nivolumab, a fully human antibody against PD-1, in the treatment of persistent or recurrent cervical cancer.
 
Alessandro Santin
No Relationships to Disclose
 
Wei Deng
No Relationships to Disclose
 
Michael M. Frumovitz
Honoraria - Genentech
Consulting or Advisory Role - Navidea; Stryker
Research Funding - Navidea
 
Warner King Huh
Consulting or Advisory Role - Antiva Biosciences; LI-COR Biosciences; Merck
 
Samir Khleif
Leadership - Advaxis
Stock and Other Ownership Interests - Advaxis
Honoraria - Cancer Panels; Genentech; INOVA Health System; MedThink
Consulting or Advisory Role - AstraZeneca/MedImmune; Gilead Sciences; Nektar; PDS
Research Funding - Advaxis (Inst); Argos Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); CureTech (Inst); MedImmune (Inst); Medivation (Inst); Merck Serono (Inst); Millennium (Inst); Newlink Genetics (Inst); PDS Biotechnology (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Newlink Genetics
 
Heather A. Lankes
No Relationships to Disclose
 
Elena Ratner
Consulting or Advisory Role - Tesaro
 
Roisin O'Cearbhaill
No Relationships to Disclose
 
Amir A. Jazaeri
Honoraria - Genentech/Roche; Neon Therapeutics
Consulting or Advisory Role - Almac Group; Aravive; Genentech/Roche
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Lion Biotechnologies (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune
 
Michael Birrer
No Relationships to Disclose